MedTrace Logo

VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment

NCT03690362 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2019-02-08

No results posted yet for this study

Summary

This is a multi-center, open-label, PK and safety study of VNRX-5133 and VNRX-5022 when co-administered in male and female subjects with varying levels of renal impairment and healthy normal controls.

Conditions

  • Pharmacokinetics

Interventions

DRUG

VNRX-5133 and VNRX-5022

intravenous infusion

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Venatorx Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-06
Primary Completion
2018-11-21
Completion
2018-11-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03690362 on ClinicalTrials.gov